Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
EditorialEditorial

Hyperferritinemia Wins Again: Defining Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus

Emily A. Smitherman and Randy Q. Cron
The Journal of Rheumatology September 2021, 48 (9) 1355-1357; DOI: https://doi.org/10.3899/jrheum.210024
Emily A. Smitherman
1E.A. Smitherman, MD, MS, Assistant Professor, R.Q. Cron, MD, PhD, Professor, Division of Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Emily A. Smitherman
  • For correspondence: Emily.Smitherman@peds.uab.edu
Randy Q. Cron
1E.A. Smitherman, MD, MS, Assistant Professor, R.Q. Cron, MD, PhD, Professor, Division of Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Randy Q. Cron
  • Article
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

REFERENCES

  1. 1.↵
    1. Henderson LA,
    2. Cron RQ
    . Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management. Paediatr Drugs 2020;22:29-44.
    OpenUrlPubMed
  2. 2.↵
    1. Ravelli A,
    2. Minoia F,
    3. Davi S,
    4. Horne A,
    5. Bovis F,
    6. Pistorio A, et al; Paediatric Rheumatology International Trials Organisation; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society
    . 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation collaborative initiative. Arthritis Rheumatol 2016;68:566-76.
    OpenUrl
  3. 3.↵
    1. Minoia F,
    2. Bovis F,
    3. Davi S,
    4. Horne A,
    5. Fischbach M,
    6. Frosch M, et al; Pediatric Rheumatology International Trials Organization, the Childhood Arthritis & Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group and the Histiocyte Society
    . Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis 2019;78:1357-62.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Parodi A,
    2. Davi S,
    3. Pringe AB,
    4. Pistorio A,
    5. Ruperto N,
    6. Magni-Manzoni S, et al; Lupus Working Group of the Paediatric Rheumatology European Society
    . Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum 2009;60:3388-99.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Gerstein M,
    2. Borgia RE,
    3. Dominguez D,
    4. Feldman BM,
    5. Liao F,
    6. Levy D, et al.
    Predicting macrophage activation syndrome (MAS) in childhood-onset systemic lupus erythematosus (cSLE) patients at diagnosis. J Rheumatol 2021;48:1450-7.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Henter JI,
    2. Horne A,
    3. Arico M,
    4. Egeler RM,
    5. Filipovich AH,
    6. Imashuku S, et al.
    HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124-31.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Bleesing J,
    2. Prada A,
    3. Siegel DM,
    4. Villanueva J,
    5. Olson J,
    6. Ilowite NT, et al.
    The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007;56:965-71.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Behrens EM,
    2. Beukelman T,
    3. Paessler M,
    4. Cron RQ
    . Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007;34:1133-8.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Zulian F,
    2. Piccinini P,
    3. Martini G,
    4. Jorini M,
    5. de Benedictis FM
    . Macrophage activation syndrome as trigger event for systemic lupus erythematosus in children. J Paediatr Child Health 2009;45:621-2.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Vilaiyuk S,
    2. Sirachainan N,
    3. Wanitkun S,
    4. Pirojsakul K,
    5. Vaewpanich J
    . Recurrent macrophage activation syndrome as the primary manifestation in systemic lupus erythematosus and the benefit of serial ferritin measurements: a case-based review. Clin Rheumatol 2013;32:899-904.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Pringe A,
    2. Trail L,
    3. Ruperto N,
    4. Buoncompagni A,
    5. Loy A,
    6. Breda L, et al.
    Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication? Lupus 2007;16:587-92.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Bennett TD,
    2. Fluchel M,
    3. Hersh AO,
    4. Hayward KN,
    5. Hersh AL,
    6. Brogan TV, et al.
    Macrophage activation syndrome in children with systemic lupus erythematosus and children with juvenile idiopathic arthritis. Arthritis Rheum 2012;64:4135-42.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Borgia RE,
    2. Gerstein M,
    3. Levy DM,
    4. Silverman ED,
    5. Hiraki LT
    . Features, treatment, and outcomes of macrophage activation syndrome in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol 2018;70:616-24.
    OpenUrl
  14. 14.↵
    1. Aytac S,
    2. Batu ED,
    3. Unal S,
    4. Bilginer Y,
    5. Cetin M,
    6. Tuncer M, et al.
    Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus. Rheumatol Int 2016;36:1421-9.
    OpenUrl
  15. 15.↵
    1. Halyabar O,
    2. Chang MH,
    3. Schoettler ML,
    4. Schwartz MA,
    5. Baris EH,
    6. Benson LA, et al.
    Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatr Rheumatol Online J 2019;17:7.
    OpenUrl
  16. 16.↵
    1. Hoyt K,
    2. Halyabar O,
    3. Han J,
    4. Case SM,
    5. Chang MH,
    6. Platt CD, et al.
    Outcomes of an evidence based guideline for the treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome [abstract]. Arthritis Rheumatol 2020;72.
  17. 17.↵
    1. Eloseily EMA,
    2. Minoia F,
    3. Crayne CB,
    4. Beukelman T,
    5. Ravelli A,
    6. Cron RQ
    . Ferritin to erythrocyte sedimentation rate ratio: simple measure to identify macrophage activation syndrome in systemic juvenile idiopathic arthritis. ACR Open Rheumatol 2019;1:345-9.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 48, Issue 9
1 Sep 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hyperferritinemia Wins Again: Defining Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Hyperferritinemia Wins Again: Defining Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus
Emily A. Smitherman, Randy Q. Cron
The Journal of Rheumatology Sep 2021, 48 (9) 1355-1357; DOI: 10.3899/jrheum.210024

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Hyperferritinemia Wins Again: Defining Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus
Emily A. Smitherman, Randy Q. Cron
The Journal of Rheumatology Sep 2021, 48 (9) 1355-1357; DOI: 10.3899/jrheum.210024
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Personalizing Management of Systemic Sclerosis–Associated Interstitial Lung Disease: Are Autoantibodies the Key for Risk Stratification?
  • Does Prior Authorization for Tocilizumab Lead to Unacceptable Treatment Delays in Giant Cell Arteritis?
  • Understanding Fatigue and Sleep Disturbance in Polymyalgia Rheumatica: Redefining the Patient Experience and Opportunities for Intervention
Show more Editorial

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire